关键词: 脑梗死; 阿托伐他汀; 基质金属蛋白酶9

Abstract: Objective To study the changes of serum matrix metalloproteinase-9 level and blood lipids level in patients with acute cerebral infarction after short treatment with atorvastatin, and study the effect of atorvastatin prognosis.Methods All 40 acute cerebral infarction patients were divided by random, double-blind, placebo contrasstive method into control group and atorvastain group (20mg/d of atorvastain for 7 days).The serum levels of MMP-9, lipids, aspartate aminotransferase(AST) and creatine kinase(CK) weredetected before and after treatment. All patients’ neurological function were evaluated by the National Institutes of Health Stroke Scale (NIHSS) score and the Barthel Index (BI) score at admission and 3 months after admission.Results 39 cases were involved in the study(control group=20, atorvastain group =19).The levels of serum MMP-9 were correlated significantly with severity and prognosis of cerebral infarction(P <0.01), but serum lipids were not correlated. The levels of serum MMP-9 in atorvastain group significantly decreased compared with those in control group(P <0.05). Deficit scales wereimproved at 3 months after treatment(P <0.01), but there were no statistical difference between atorvastain group and control group . AST and CK levels had no changes after treatment.Conclusion The levels of serum MMP-9 are associated with severity and can predict prognosis of acute cerebral infarction. Short treatment with atorvastain can rapidly and safely reduce the serum level of MMP-9, but there is no significant improvement in 3-month prognosis after cerebralinfarction.

Key words: Cerebral infarction; Matrix metalloproteinase-9; Atorvastain